RxDoctor Payments Data

Connie Carlstrom

Adult Health · Bedford, TXNPI 1164424610

Payments from drug & device makers

$3,127in general payments, 2019–2025

Across 146 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$378
  • Esperion Therapeutics, Inc.$374
  • Medtronic$325
  • Abbott$310
  • Novartis$300
  • Merck$257
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,112100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,127 in reported general payments places this provider in the 80th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$75,418
Medicare patients
582
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$320,917
XareltoRivaroxaban100$122,514
EntrestoSacubitril/Valsartan45$47,464
JardianceEmpagliflozin25$38,277
Repatha SureclickEvolocumab44$31,246
Ranolazine ErRanolazine41$4,558
Metoprolol Succinate313$3,973
Flecainide Acetate65$3,766
Nebivolol Hcl49$3,063
Rosuvastatin Calcium126$2,165
Losartan Potassium179$1,975
Amlodipine Besylate204$1,714
Valsartan93$1,703
Carvedilol172$1,691
Bisoprolol Fumarate57$1,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$320,917274 claims
Johnson & JohnsonXarelto$178$122,514100 claims
NovartisEntresto$300$47,46445 claims
Boehringer IngelheimJardiance$98$38,27725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 933 adult health providers in Texas.

Other adult health in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →